Videos

Focused Radiation Has ‘Good Success’ for Metastatic Kidney Cancer

November 14th 2023, 11:00pm

Stereotactic radiation is promising in treating patients with metastatic kidney cancer and may delay the time until patients need further treatment, an expert said.

Individualized Treatment Selection in Cervical Cancer

November 14th 2023, 5:10pm

Expert perspectives on how to best match the right treatment with the right patient with cervical cancer.

Treatments for Patients With Newly Diagnosed Metastatic Cervical Cancer

November 14th 2023, 5:03pm

Clinical insights on treatment options for patients with newly diagnosed metastatic cervical cancer, with a focus on immunotherapy and the KEYNOTE-826 trial.

Positive Outlook for the Future

November 9th 2023, 2:00pm

Dealing with Adverse Events Associated with Sacituzumab Govitecan

November 8th 2023, 11:00pm

Treatment Options for Patients With Primary or Recurrent Cervical Cancer

November 7th 2023, 5:16pm

Experts on cervical cancer discuss treatment options for patients with primary or recurrent cervical cancer and review the GOG 240 study.

Patient Perceptions of Cervical Cancer Screening

November 7th 2023, 5:11pm

The expert panel discusses ways doctors can make cervical cancer screening easier in terms of access and the patient experience.

Considerations for Enrolling into a Clinical Trial

November 5th 2023, 2:00pm

Valerie Frank and Sara M. Tolaney, MD, MPH, share advice for patients on managing treatment with antibody-drug conjugates and the importance of participating in clinical trials for HR+/HER2- metastatic breast cancer.

Multidisciplinary Approach to Disease Management

November 4th 2023, 1:00pm

Valerie Frank and Sara M. Tolaney, MD, MPH, share advice for patients on managing treatment with antibody-drug conjugates and the importance of participating in clinical trials for HR+/HER2- metastatic breast cancer.

Initial Diagnosis of HR+/HER2- Breast Cancer

November 3rd 2023, 10:00pm

Valerie Frank and Sara M. Tolaney, MD, MPH, share advice for patients on managing treatment with antibody-drug conjugates and the importance of participating in clinical trials for HR+/HER2- metastatic breast cancer.